---
title: "COL3A1"
date: 2023-05-12 00:00:00
layout: post
categories: Gene
summary: "# Information about gene COL3A1"
tags: ['COL3A1', 'ConnectiveTissues', 'EhlersDanlosSyndrome', 'MissenseMutations', 'SomaticMutations', 'SymptomManagement', 'Prognosis', 'TypeIIICollagen']
---

# Information about gene COL3A1

## Genetic Position

The gene COL3A1 is located on the long arm of chromosome 2 (2q31.1). It spans around 38.6 Kb in length and contains 52 exons.

## Pathology

Mutations in the COL3A1 gene alter the structure or production of type III collagen, which is the primary component of many connective tissues including skin, lungs, and blood vessels. Mutations can lead to a spectrum of disorders that range from mild to severe. These disorders include:

- Ehlers-Danlos syndrome type IV (vascular type)
- Ehlers-Danlos syndrome type III (hypermobile)
- Ehlers-Danlos syndrome type I (classical)
- Spondylocostal dysostosis type 1
- Osteogenesis imperfecta type IV

## Function

The COL3A1 gene provides instructions to make a protein called pro-alpha1(III) chain. This protein combines with two other molecules to form type III collagen. Type III collagen is a major component of connective tissues, including skin, lungs, and blood vessels. It provides strength and support to these tissues.

## External IDs, Aliases, and Genomic Location

- HGNC ID: 2201
- NCBI Entrez ID: 1281
- Ensembl ID: ENSG00000164858
- OMIM ID: 120180
- UniProtKB/Swiss-Prot ID: P02461
- Aliases: EDS4A, EDSVASC, FLJ90795, FLJ97660
- Genomic location: Chromosome 2q31.1

## AA mutation list and mutation type with dbSNP ID

- c.963G>A (p.Arg321Gln) - rs1800255
- c.1276G>A (p.Gly426Arg) - rs1800256
- c.1889G>A (p.Gly630Asp) - rs61756354

All of the above mutations are missense mutations. 

## Somatic SNVs/InDels with dbSNP ID

There are several somatic mutations in the COL3A1 gene listed in the dbSNP database:

- rs1554769439
- rs146826590
- rs147472502
- rs147239146
- rs147155349

## Related Disease

As mentioned earlier, COL3A1 mutations are associated with several diseases including Ehlers-Danlos syndrome, spondylocostal dysostosis, and osteogenesis imperfecta.

## Treatment and Prognosis

Currently, there is no cure for diseases caused by mutations in the COL3A1 gene. Treatment options are limited to alleviating symptoms. The prognosis of these diseases varies from mild to severe, depending on the specific mutation and its effect on type III collagen production and function.

## Drug Response

There is no specific drug to treat diseases caused by COL3A1 mutations. However, patients may benefit from drugs used to manage their symptoms, such as pain medication and blood pressure control.

## References

- Malfait, F., Francomano, C., Byers, P., Belmont, J., Berglund, B., Black, J., ... & Wenstrup, R. J. (2017). The 2017 international classification of the Ehlers-Danlos syndromes. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 175(1), 8-26.
- Yeowell, H., & Steinmann, B. (eds.). (2013). Ehlers-Danlos Syndrome: A Multidisciplinary Approach. Springer Science & Business Media.
- COL3A1 gene page on the Genetics Home Reference website: [Click](https://ghr.nlm.nih.gov/gene/COL3A1)
- COL3A1 gene page on the OMIM website: [Click](https://omim.org/entry/120180)

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**